New drug targets two cancer proteins in advanced tumors
NCT ID NCT07700160
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study has two parts: first, finding the safest dose, and then testing how well that dose works against different types of solid tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VBC108
- What this could lead to
- If it works, this could provide a new treatment option for people with advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is an early-phase trial, so the drug may not be effective or could cause serious side effects. The results may not apply to all cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GenesisCare North Shore
St Leonards, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Laura and Issac Perlmutter Cancer Center
New York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Virginia
Fairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Next Oncology - Oncology
San Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
One Clinical Research
Perth, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Midwest, LLC
Grand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
- Can a cancer vaccine train the body to fight advanced tumors?